Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19580400 | 0.82 | KEAP1 (0.35) | ATM | |
| SCHEMBL4343962 | 0.82 | KEAP1 (0.35) | ATM | |
| SCHEMBL25183055 | 0.81 | GPR3 (0.38) | MAPTATM | |
| SCHEMBL25182326 | 0.81 | GPR3 (0.38) | MAPTATM | |
| SCHEMBL28669006 | 0.80 | ABCB1 (0.36) | IDO1 | |
| SCHEMBL28669009 | 0.80 | ABCB1 (0.36) | IDO1 | |
| SCHEMBL30510269 | 0.80 | GPR3 (0.41) | MAPTATM | |
| SCHEMBL1830100 | 0.80 | GPR3 (0.41) | MAPTATM | |
| SCHEMBL30510362 | 0.80 | GPR3 (0.41) | MAPTATM | |
| SCHEMBL4603276 | 0.80 | GPR3 (0.41) | MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570317-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2025-06-18 | — | — | EP | disclosed |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11406617-B2 | Compounds for the treatment of bovine or swine respiratory disease | INTERVET INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | INTERVET INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3558284-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115432-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INTERNATIONAL B.V. (NL) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11406617-B2 | Compounds for the treatment of bovine or swine respiratory disease | PIGS, BTD, PPARD | IDO1 1321/4885GABRB1 836/4885GABRB2 1001/4885 |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, BRD1 | IDO1 1873/4885GABRB1 1062/4885GABRB2 1226/4885 |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | PIGS, BTD, PPARD | IDO1 1321/4885GABRB1 836/4885GABRB2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.